Lantern Pharma Q1 2023 Earnings Call Transcript

Quartr
Provided by Quartr
May 9, 2023

There are 2 speakers on the call.

Operator

You have joined the meeting as an attendee and will be muted throughout the meeting. I would like to remind everyone that remarks about future expectations, performance, estimates and prospects constitute forward looking statements for purposes of Safe Harbor provisions under the Private Securities Litigation Reform Act of 1995. Plantronics Pharma cautions that these forward looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those anticipated. A number of factors could cause actual results to differ materially from those indicated by forward looking statements, including the impact of the COVID-nineteen pandemic, results of clinical trials and the impact of competition. Sufficient information concerning factors that could cause actual results to differ materially from those in the forward looking statements can be found in our annual report on Form 10 ks for the year ended December 31, 2022, which is on file with the SEC and available on our website.

Operator

Forward looking statements made on this conference call are as of today, May 9, 2023, and Land and Pharma does not intend to update any of these forward looking statements to reflect events from circumstances that occur after today unless required by law. The webcast replay of the conference call and webinars will be available on Manchin's website. On today's webcast, we have Manchin Pharma's CEO, Pana Sharma NCSO, David Margrease. Hannah will start things off with an overview of Lantern's strategy and business model and highlight recent achievements in our operations, after which David will discuss our financial results. This will be followed by some concluding comments from Hana, and then we'll open up the call for Q and A.

Operator

I'd now like to turn the call over to Pana Shanamal, President and CEO of Mainstream Pharma. Pana, please go ahead.

Speaker 1

Thank you, Nicole. Good afternoon, everyone, and welcome to our Q1 2023 earnings call and company update. We've had a tremendously progressive and productive quarter. I want to tell you all about the corporate progress so far at Lantron Pharma. Lantron Pharma is at the leading edge leveraging artificial intelligence, machine learning algorithms, biomarker clinical, genomic and drug response data to transform the costs, compress the timelines and derisked oncology drug discovery and development.

Speaker 1

During the Q1, we made many exciting and valuable advances to our platform And our pipeline of cancer therapies. Our team continues to be extremely focused on taking these insights for our new programs And driving them to meaningful clinical programs that can be launched in the coming months for both LP-one hundred and eighty four and LP-two eighty four. We've done this for both molecules and a fraction of the time and a fraction of the cost of traditional drug development. And what we're also practicing is the future of oncology therapy development, where data can be used to accelerate programs and derisk the identification and progress of potentially life changing medicines. My colleagues at Lantern and I are united in a core belief that a rise in sophisticated, highly scalable, analytical storage technologies, coupled with high value data from cancer biology research and genomics, along with the decrease in the cost of AI computing, is allowing us to do 2 very important things: better model, understand and predict cancer biology And secondly, design and develop cancer drug programs at a fraction of the cost and a fraction of the time line that had traditionally been possible.

Speaker 1

This is true not only in cancers that have been well researched and highly characterized, but also in cancers that have traditionally gone under met or unresolved. As I know from talking with investors, analysts and our partners, what's in everyone's mind right now or at least many people's mind is Chat GPT, A very sophisticated model of language that's generative and real time and allows us to understand huge swaths of data, everything on the Internet Or even off of the Internet, all in one place and interacting in a pretty compelling and interesting way with all of us, Not only us as humans and end users, but also very importantly with us as researchers, developers, clinicians and scientists. And this is being done at a scale that was never thought possible before and never had a level of precision, automation and cost as today. The technologies and tools that make up those large language models, data automation and analytics are the same approaches in AI technologies we believe That we are leveraging and deploying to create new drug programs and cancer biology insights at a cost and time line that was unimaginable in the near past. Today at Lantern, we had a highly massive scale, think from highly massive scale, millions of simultaneous instances of competing algorithms that are working to help create correlations and relationships that would be far too complex and time consuming for any team of humans to fully approach, Let alone replicate with precision.

Speaker 1

Right now, we can understand and predict parts of these drug interactions with cancers, But not all of it has a complete system with or with the required level of personalization. That's why we're constantly on the hunt for new data, curating it, ingesting it, evolving our systems. And we are evolving not only the underlying data and datasets and data tags, but also the algorithms. We're also now training the algorithms to update themselves and also finding methods in which we can allow the AI platform defining and ingest new data on its own. This is the future of developing cancer therapies where data can be used to accelerate programs, derisk the identification and progress of potentially life changing medicines and potentially find new patient groups or new patient classes That can have a big impact from our therapies or therapies of our partners.

Speaker 1

During the quarter, we made some very meaningful progress. Let me give you some of the highlights. We dosed the first patients in the Phase II HARMONIC clinical trial, a study for the unique population are not. Of non small cell lung cancer patients who are never smokers, and they make up about 15% to 20% of all lung cancer cases in the U. S.

Speaker 1

Today. We submitted the we're about to submit the IND application for LP-one hundred and eighty four to the U. S. Food and Drug Administration. We anticipate submitting that this week.

Speaker 1

This is for a potential blockbuster therapy with $6,000,000,000 to $7,000,000,000 In annual sales, we'll look to use it both as a single agent or as a combination therapy. This Phase 1 clinical reprocessor LP184 in genomically defined solid tumors will be launching in mid-twenty 23 for patients with a recurrent solid tumors, including brain cancers. We also plan on completing our IND enabling studies for LP284 And launching a 1st in human Phase 1 clinical trial in multiple non Hodgkin lymphoma. This is about a $1,200,000,000 indication And this is targeted in the second half of this year. We also received notice of allowance from the U.

Speaker 1

S. PCO for composition of matter patents for LP284 as well. This gives us exclusivity for this new molecule into 2039, 2014. We also developed an industry leading series of AI algorithms. These are a series of algorithms that not only are now top ranking at the therapeutic data commons, which is an industry consortium, but it helps solve one of the most challenging problems in brain cancer drug discovery, Which is predicting with some low of accuracy, it compounds blood brain barrier permeability.

Speaker 1

Our top four algorithms are not only highly accurate, but also ultra fast and scalable. We can run thousands of molecules at a level and scale that was not possible before on a daily basis. We also established an additional RADAR collaboration. We're certainly one of the leaders in breast cancer, TTC Oncology, to help advance their Phase 2 ready drug candidate, PTC352, in ER positive breast cancers. This continues to prove and validate that in fact our AI platform radar is valuable currency in deal making and enjoying asset development.

Speaker 1

We also continued to show fiscal discipline and ended the quarter with $51,500,000 in cash, cash equivalents and marketable securities, given that cash flow going into 2025. Now with those highlights behind us, let me turn the call over to our CFO, David Margrave will provide an overview of our Q1 financial results. David? Thank you, Pana, and good afternoon, everyone. I'll now share some financial highlights from our Q1 ended March 31, 2023.

Speaker 1

Our R and D expenses were $2,600,000 for the Q1 of 2023, down slightly from $2,700,000 in the Q1 of 2022. We see R and D expenses increasing in the second half of twenty twenty three As we advance our LP300 Phase II trial and commence our Phase I trials for LP184 And LP284. General and administrative expenses were $1,700,000 For the Q1 of 2023, up slightly from $1,400,000 in the prior year period. We recorded a net loss of $3,900,000 for the Q1 of 2023 or $0.36 per share Compared to a net loss of $4,100,000 or $0.38 per share for the Q1 of 2022. Offsetting the loss from operations in the Q1 of 2023 With interest income and other income net in the aggregate amount of $419,000 Interest income was approximately $134,000 for the Q1 of 2023.

Speaker 1

Other income net was are approximately $285,000 for the Q1 of 2023 and reflected increases in dividend income of approximately 80 $1,000 increases in unrealized gains on investments of approximately $207,000 And increases of approximately $136,000 in research and development tax incentives related to our Australia subsidiary. These were offset in part by increases in foreign currency losses of approximately $60,000 As of March 31, 2023, we had approximately 10,860,000 shares of common stock outstanding And outstanding warrants to purchase approximately 177,998 shares And outstanding options to purchase approximately 1,095,046 shares. These warrants and options, combined with our outstanding shares of common stock, give us a total fully diluted shares outstanding Of approximately 12,100,000 shares as of March 31, 2023. Our cash position, which includes cash equivalents and marketable securities at March 31, 2023, It's $51,500,000 This balance is expected to carry us into 2025. Importantly, We believe our solid financial position will fuel continued growth and evolution of our Radar AI platform, accelerate the development of our portfolio of targeted oncology drug candidates and allow us to introduce additional targeted products and collaboration opportunities in a capital efficient manner.

Speaker 1

Our team continues to be very productive under a hybrid operating model. This hybrid model also removes geographic restrictions to our hiring initiatives, which gives us the ability to recruit extremely high caliber team members that otherwise might not be available. We currently have 23 employees who are primarily focused on leading and advancing our research and development efforts. We see this number expanding slightly in coming quarters as we add additional experienced and talented individuals to help advance our mission. I'll now turn the call back over to Pana for an update on some of our development programs.

Speaker 1

Pana? Thank you, David. As we mentioned earlier in the call, this week, we'll be submitting our IND application to the FDA for LPOne A's first in human trial for advanced solid tumors and brain cancers. On average, we've been able to advance our newly developed drug programs from initial AI insights the first in human clinical trials in 2 plus years at a cost of around $1,000,000 to $2,000,000 per program. Both metrics that are completely unheard of in oncology drug discovery.

Speaker 1

This breakthrough pace of development was most recently highlighted in Starlight Therapeutics as it intends to pursue human clinical trials for multiple CNS indications starting in late 2023, Building on prior IND enabling studies and the upcoming Phase 1a clinical testing that will be conducted by Rancho in the coming months. The clinical development of SARS-one in CNS cancers beyond, the Phase 1a trial will be conducted exclusively by Starlight. But following that, Lantron will continue to advance LP-one hundred and eighty four's preclinical and clinical development for non CNS indications, Including pancreatic, bladder, triple negative breast cancer and other solid tumors that have DNA damage repair deficiencies. The formation of Starlight as a wholly owned subsidiary allows Ranger to sharpen the focus on advancing STAR001 are targeted clinical trials and dedicate increased time, resources and personnel to progress one of the most promising drug candidates for CNS cancer patients in decades. We believe that by focusing our efforts by Starlight, we can accelerate and deepen our commitment to the CNS cancer patient community, while also creating the potential for meaningful additional upside for our investors.

Speaker 1

We'll always be looking for additional opportunities where the development needs and unique focus of certain programs or assets can be separated and developed in a more focused and perhaps more evolved manner. As we've pointed out, we're accelerating the pace at which we're developing, Validating our insights and then leading those as potentially meaningful and breakthrough drug assets. We're very well positioned to partner these drug assets out with larger companies and we'll begin exploring some of those licensing and partnership opportunities with biopharma companies this year. Other objectives for us this year will continue We'll be to continue expanding radar to beyond 50,000,000,000 data points. We do establish additional radar based collaborations And also advance our ADC preclinical ADC development, both through advances in our platform, but also advances in exciting new preclinical compounds that we'll talk about later this year.

Speaker 1

At the same time, Dave pointed out in his review, our strong cash position is being carefully utilized to make meaningful progress in a disciplined manner. The most exciting which are coming up, which is scaling to more patients for LP-three hundred and launching LP-one hundred and eighty four in a clinical setting. Now with that, I'd like to open up the call to any questions.

Operator

Thank you, Hannah. If you would like to ask a question, you can do so in 1 of 2 ways. You can either type your question in using the Q and A tool or you can click on the raise hand tool to speak directly to management and I will allow you to speak. We have a question coming in here from an investor about our data in radar. Where do we source our data and how do we validate and clean it.

Speaker 1

That's a great question. So we get our data not only from public sources like TCGA and CCLE and the NCI, but also some private sources such as collaborations that we have, Our own sequencing and biomarker studies that we do routinely with all of our drug programs and with our CRO partners. We also get it from different studies that are posted at places like AACR, ASCO, etcetera. We also get them from historical drug programs and historical trials. So there's a number of different places, including our own proprietary data that we're generating, Both preclinical and clinical data.

Speaker 1

And validating that data is interesting. Obviously, we run our studies I mean duplicate to make sure the data we are getting is reliable. We also know that a lot of historical data is not terribly reliable or has its own challenges. So we embarked a few years back on a massive cleanup of all of our Of all of our NCI and CCLE and other historical TCGA related data sources. And so we normalize and recuraged a lot of that data.

Speaker 1

We also threw a lot of it away. One of the very first things I did when I joined Lantern It's about 30% of the data that we had at the time was tossed because it was not reliable enough for a change in cell lines that were Unknown or dubious in nature. And these are pretty well known in the industry, so most people who use data Either work around it, clean it, or duplicate it, which is pretty normal. But what we've done, which is unusual, is we've gone through tons of tagging when we give each of the datasets a data quality score. So we know what machine it comes from, what labs, where it was generated, how it was published, are not.

Speaker 1

Publishing duplicate, did we transform the data? So we have multiple ways that we not only curate, but then clean And normalize the data so that we can use it.

Operator

I see here Michael King is raising his hand. Michael, you should be able to speak.

Speaker 1

Can you hear me? Yes. Hi, guys. I wanted just to ask you to speak about partnering strategies. I just was wondering where your sweet spot or where you think the sweet spot is in terms of Public, private, academic, etcetera, companies and other institutions to, you know, to source further assets for the pipeline, or are you better or maybe simultaneously do deals based around radar And other people's compounds.

Speaker 1

That's a great question. So I'm going to give you a lengthy answer. We can Talk more about it at your conference later this week, Michael. So in terms of Ingest, new molecules, new ideas, We have ideas of what things are a higher priority for us than others. And so we try to see if those things are out there, they're available and they've been manufactured, they've been tested, they've become a biological data that then puts us ahead of the game.

Speaker 1

So yes, there are definitely certain areas. And we're always open to learning new things. You're only as, Your question is only going to be as good as the data you have. So of course, we're always looking at new assets as well. But they all do go through radar.

Speaker 1

So if you look at the unique relationship we have with TTC, although we are helping them with the definition of The patients that are most likely to respond to their drug and also how their drug can be used in other indications, We also do have a clause in where it allows us to potentially license and co develop the asset. So as we develop it into Some meaningful radar driven insights. We do try to always have that clause that's basically Executable to try to get that asset through radar. In terms of licensing out, our goal is either Phase 2 or Phase 3 to license it out The bigger biopharma companies that will then take the asset, whatever molecular signatures that we have, etcetera, that make it meaningful and then put it into Later stage trials. So hopefully that answers your question.

Speaker 1

Yes. Thanks so much for taking it.

Operator

A few other questions coming in here, one from John Vandermosten. How are some of the characteristics that Radar has identified in compounds that are able to cross the BBB.

Speaker 1

That's a great detailed question. So Jim, I'll be able to send you a white paper. We look at Probably somewhere in the range of between 4,000 5000 different characteristics. Everything simple characteristics like weight and size The number of carbon rings, surface area of the carbon rings, Whether it's an enhancement run, there's like somewhere between 4,005,000 different characteristics, and we try to boil those down to the most important ones. But we use multiple algorithms.

Speaker 1

It's not just the characteristics, different algorithms that prefer different characteristics. And then we also run an ensemble approach. If you look at therapeutic data commons, which I urge you to look at, the top performing algorithm right now is the Ensemble algorithm, Which means it's a mash up of the 3 or 4 other algorithms that all come right underneath it. And so The so these molecular fingerprints and these unique things that each Chemical, it has come from its structure, from its smiles characteristics. And then we Basically, you draft all that and decide which of the few 1,000 are most important.

Speaker 1

Hopefully, that answers your question.

Operator

Another one here from John regarding the AACR abstract on LP-one hundred and eighty four. The related study suggests about using combination approaches with PARP inhibitors for other agents that disrupt damage repair pathways.

Speaker 1

So can you put the question back up? Thanks. Again, regarding the ACRS, right, does the related study suggest about Using combination with PARP inhibitors or other agents. Yes, I think PARP5, because there are a number of PARP5s that are approved there, That's where we're actually actively exploring 184 and potentially 100 both with Part Buy Drugs. There's a big opportunity because number 1, they're already approved.

Speaker 1

They're selling in the billions And we know that there's dosage issues with PARP inhibitors. People become sensitive and there's some toxicity issues. So we're in discussions with some of the CARB I investigators to look at combination of 184. Now one of the unique things that came out in the AACR I think it's not as clear as we'd like, but definitely hinted at, it will come out in the next set, is that the PARP inhibitors, they The molecules, let's say, the cancer cells from repairing themselves, they're great blockers of repair. And so that's what gives it the cancer cell kind of capability.

Speaker 1

Now interestingly enough, LP1804 is a great breaker of DNA double strands. And so as it breaks the double strands And then the Part 5s are dosed and the Part 5s keep the double strands from repairing. It's like a really perfect one to hit. And that's why we like the 184 plus club I combination. Could other global strand breaking agents be used?

Speaker 1

Yes, perhaps, drugs and trobriosomalases, maybe some M and AEs, but those have tremendous amounts of toxicity. And so you're going to get toxicity side effects from both those drugs that are just not good. That's what makes 194 more unique, Especially when using Part V because it's complementary mechanisms, and we're also able to, we believe, Change the dosage level significantly. So this is an area we're very excited about.

Operator

Another question coming in here. Our cash runway hasn't changed through our last few quarters. Can you sound on that a bit.

Speaker 1

I wish that was 100% true, but we have the approval with our cash, but I'll let David cannot walk you through the Boerne between $3,000,000 $4,000,000 roughly a quarter. But David, go ahead. Sure. As we described on the call, We have about $51,500,000 in cash, cash equivalents and marketable securities at the end of the quarter. And we have been consistent and I think pretty solid in our forecasting in terms of where our cash would carry us.

Speaker 1

We've managed that very carefully. And I think the reality is compared to a large portion As our sector, we are in a very strong cash position. We're always looking for We're watching this cash position very carefully. We're looking for opportunities, and we'll continue to operate in a very fiscally disciplined

Powered by Quartr
Earnings Conference Call
Lantern Pharma Q1 2023
00:00 / 00:00